Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global
innovator in drug delivery platforms, this morning announced the initiation of
a program, in collaboration with leading laboratories in Canada and the USA, to
analyze the benefits of Lexaria’s DehydraTECH(TM) drug delivery platform for
improving delivery and effectiveness of certain antiretroviral drugs in the
fight against coronavirus disease COVID-19. Researchers around the world are
currently examining several antiretroviral drugs, many of which are fat
soluble, as possible candidates to combat COVID-19. When administered in oral
form, fat soluble drugs are known to present considerable bioavailability
challenges in effectively reaching the human bloodstream. Lexaria is an
established leader in oral delivery of fat-soluble drugs. Lexaria plans to
conduct a pilot human pharmacokinetic exploratory study in healthy volunteers
of three antiretroviral drugs that have previously been studied against other
coronavirus strains, assessing DehydraTECH formulations against controls
without the technology. The company intends to conduct the study at a leading
Canadian University where a study design and plan has already been submitted
for ethics board approval. The company has held discussions with some
laboratories that could potentially expand the number of prospective drugs
using DehydraTECH under evaluation for coronavirus applications. Following
positive conclusions from its planned research activities, Lexaria will
aggressively engage with prospective strategic partners to enhance drug development
where applicable.
To view the full press release, visit http://ibn.fm/7gOan
About Lexaria
Lexaria Bioscience Corp. is a global innovator in drug
delivery technology. Its patented DehydraTECH(TM) drug delivery technology
changes the way active pharmaceutical ingredients enter the bloodstream,
promoting healthier ingestion methods, lower overall dosing and higher
effectiveness for lipophilic active molecules. DehydraTECH increases
bio-absorption; reduces time of onset; and masks unwanted tastes for orally
administered bioactive molecules including nicotine, vitamins, non-steroidal
anti-inflammatory drugs (NSAIDs) and other molecules. Lexaria has licensed
DehydraTECH to multiple companies for use in various oral application formats,
including to a world-leading tobacco producer for the development of smokeless,
oral-based nicotine products. Lexaria operates a licensed in-house research
laboratory and holds a robust intellectual property portfolio with 16 patents
granted and over 60 patents pending worldwide. For more information, visit the
company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment